EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Gemtuzumab Ozogamicin for Patients with Newly Diagnosed CD33‐Positive Acute Myeloid Leukemia: A French Retrospective Observational Study

Juliette Lambert, Emmanuel Raffoux, Delphine Lebon, Thorsten Braun, Maël Heiblig, Alberto Santagostino, Anne Vekhoff, Karïn Gogat-Marchant, Cécile Pautas iD

eJHaem · 2026-12 · 7 (6)

DOI: 10.1002/jha2.70454 ↗

Kurz gefasst

Fachartikel in der Zeitschrift eJHaem, online erschienen am 14.11.2026. Verfasst von Juliette Lambert und 8 weiteren Autor:innen. Beteiligte Einrichtung: Service d'Hématologie Clinique Centre Hospitalier de Versailles Le Chesnay France. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Gemtuzumab ozogamicin (GO), a CD33‐targeted antibody–drug conjugate, is approved in combination with daunorubicin/cytarabine for patients ≥ 15 years with de novo, CD33‐positive acute myeloid leukemia (AML).

Methods

This retrospective, observational study assessed real‐world use, clinical outcomes, and safety of GO in 113 patients with de novo AML treated between 2014 and 2022 in the French authorization for temporary use (ATU) and post‐ATU program.

Results

During first induction, most patients (98.1%; 105/107) received GO with other agents, mainly daunorubicin/cytarabine (60.0%; 63/105). After 44.6 months’ median follow‐up (95% CI: 33.8–69.3), 78.6% (88/112) responded; 72.3% (81/112) achieved complete response, 52.2% (24/46) without measurable residual disease. Median (95% CI) event‐free survival (EFS), relapse‐free survival (RFS), and overall survival (OS) were 13.1 months (9.9–17.5), 17.5 months (12.6–35.6), and 49.8 months (21.8–not estimable), respectively. Overall, 46.9% of patients died. Older age predicted shorter OS ( p < 0.001). FLT3‐TKD mutation ( p = 0.013) and adverse cytogenetic classification ( p = 0.015) predicted shorter EFS. ECOG performance status ≥ 2 ( p = 0.005) and adverse cytogenetic classification ( p = 0.001) predicted shorter RFS. Forty‐four patients (38.9%) reported ≥ 1 adverse event of interest; 13.3% were serious and 26.6% treatment‐related; most commonly thrombocytopenia (21.2%). GO was predominantly administered per indication. No new safety signals were reported.

Conclusions

Results demonstrate real‐world safety and clinical outcomes of GO plus induction therapy for patients with de novo CD33‐positive AML. Trial Registration EU Post Authorization Study (PAS) register number: EUPAS44551

Schlagwörter

Stichwörter der Autor:innen

acute myeloid leukemiagemtuzumab ozogamicinreal‐world

Autor:innen und Institutionen

  • Service d'Hématologie Clinique Centre Hospitalier de Versailles Le Chesnay France.
  • Service d'Hématologie Clinique Hôpital Saint-Louis Institut De La Leucémie Paris France.
  • Service d'Hématologie Clinique Centre Hospitalier Universitaire Amiens-Picardie Amiens France.
  • Hematology Unit Avicenne Hospital University Sorbonne Paris Nord Bobigny France.
  • Service d'Hématologie Clinique Hôpital Lyon Sud Pierre Bénite France.
  • Hématologie Clinique Hôpital Simone Veil Troyes France.

ORCID-Profile: Cécile Pautas

Förderung

  • Pfizer

Zitieren

APA

Lambert, J., Raffoux, E., Lebon, D., Braun, T., Heiblig, M., Santagostino, A., Vekhoff, A., Gogat-Marchant, K., & Pautas, C. (2026). Gemtuzumab Ozogamicin for Patients with Newly Diagnosed CD33‐Positive Acute Myeloid Leukemia: A French Retrospective Observational Study. eJHaem, 7(6). https://doi.org/10.1002/jha2.70454

Vancouver

Lambert J, Raffoux E, Lebon D, Braun T, Heiblig M, Santagostino A, et al. Gemtuzumab Ozogamicin for Patients with Newly Diagnosed CD33‐Positive Acute Myeloid Leukemia: A French Retrospective Observational Study. eJHaem. 2026;7(6). doi:10.1002/jha2.70454

BibTeX
@article{Lambert2026,
  author = {Lambert, Juliette and Raffoux, Emmanuel and Lebon, Delphine and Braun, Thorsten and Heiblig, Maël and Santagostino, Alberto and Vekhoff, Anne and Gogat-Marchant, Karïn and Pautas, Cécile},
  title = {Gemtuzumab Ozogamicin for Patients with Newly Diagnosed CD33‐Positive Acute Myeloid Leukemia: A French Retrospective Observational Study},
  journal = {eJHaem},
  year = {2026},
  volume = {7},
  number = {6},
  doi = {10.1002/jha2.70454}
}
Kostenlos starten →